Skip to main content

Table 3 Literature review on invasive micropapillary carcinoma of the breast

From: Prognosis of lymphotropic invasive micropapillary breast carcinoma analyzed by using data from the National Cancer Database

Study Cases Age (years)a ER+ (%) PR+ (%) HER2+ (%) RLN+ (%) DSS (%) OS (%) Follow-up durationa
NCDB (current study) 1818 60 84.3 73.9 19.4 55.2 87.5 at 5 years 4 years
Kim et al. [2] 38 47.3 19.4 19.4 78.9
Chen et al. [3] 624 61.7 84.8 69.9 52.9 92 at 5 years 84 at 5 years 33.0 months
Yu et al. [5] 267 47 66.3 66.3 28.8 62.9 97.7 at 5 years 59 months
Chen et al. [6] 95 58.9 83.2 74.7 21.1 72.6 81.9 at 5 years 60 months
Shi et al. [7] 188 52.7 85.1 78.2 29.9 73.4 75.9 at 5 years 40.5 months
Cui et al. [8] 25 52.3 88 64 80 36.5 months
Walsh & Bleiweiss [37] 80 58.8 90.6 70.3 59.1 72.3
Vingiani et al. [38] 49 52.7 87.8 69.4 18.4 69.4 89.8 at 6 years 6 years
Adrada et al. [39] 29 56a 82 61 43 62
Chen et al. [40] 100 50 46 27 84.8 63.3 59 at 5 years 60.1 months
De La Cruz et al. [41] 16 50.9 50 31.2 50 92.9 75 38 months
Luna-Moré et al. [42] 68 54.3 74.5 46.3 90.5 63 52.6 months
Middleton et al. [43] 14 50 25 12.5 70 at 5 years 57.6 months
Nassar et al. [44] 83 61 71 77 40 46 7 years
Paterakos et al. [45] 18 55 61.1 < 50 95.2 50 at 44 months 165.6 months
Pettinato et al. [46] 62 57 32 20 95 90 49 5.2 years
Yamaguchi et al. [47] 15 60.1 73 67 33.3 46.6
Zekioglu et al. [48] 53 52.5 68 61 68.8 72 56.5 months
  1. ER estrogen receptor, + positivity, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, RLN regional lymph node metastasis, DSS disease-specific survival, OS overall survival, NCDB National Cancer Database, – not available or not reported
  2. aMedian or mean age